ME Stock Recent News
ME LATEST HEADLINES
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”
23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since going public three years ago, with shares plummeting by over 90% amid sluggish adoption of its personalized DNA services.
23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) filing.
23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private
Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely.
23andMe co-founder and chief executive Anne Wojcicki is considering making an offer to buy the genetics testing company in a potential go-private transaction, a regulatory filing on late Wednesday showed.
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23ME-01473 targeting ULBP6, and 23ME-00610 targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024.
Shares of 23andMe have been hurt severely since the company's stock market debut in 2021. Several billionaire investors acquired shares of 23andMe during the last three months of 2023.
The at-home genetic testing company is dealing with financial woes and a security breach. What does that mean for customers?